Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Status Recruiting

Clinical Trial Summary

This study is being done to find the effect of Dibenzyl Trisulphide (active ingredient in Guinea Hen Weed in combination in patients with stage four cancer of the breast, prostate, cervix and colon.

Clinical Trial Description

There have been many claims of the value of Guinea Hen weed in the treatment of different cancers. The preparation is readily available and used locally. The team proposes to validate the studies done on cancer cell lines by conducting a clinical trial to determine the clinical benefit in advanced and metastatic cancers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04113096
Study type	Interventional
Source	The University of The West Indies
Contact	Horace Fletcher, MBBS/DM
Phone	876 927 1145
Email	horace.fletcher@uwimona.edu.jm
Status	Recruiting
Phase	Early Phase 1
Start date	October 1, 2018
Completion date	September 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01987726` - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Terminated	`NCT01918306` - GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer	Phase 1/Phase 2
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Terminated	`NCT01222377` - Endoscopic Breast Surgery in Treating Patients With Breast Cancer	N/A
Completed	`NCT00602043` - F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer	Phase 2
Completed	`NCT00096109` - Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer	Phase 2
Completed	`NCT00244881` - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	Phase 2
Completed	`NCT00100750` - Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT00425672` - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment	Phase 1/Phase 2
Completed	`NCT00096434` - Sorafenib in Treating Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT00057941` - Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer	Phase 2
Terminated	`NCT02892734` - Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer	Phase 2
Recruiting	`NCT03213041` - Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer	Phase 2
Completed	`NCT02015559` - Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus	Phase 2
Completed	`NCT02728596` - S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	N/A
Completed	`NCT03364348` - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer	Phase 1
Completed	`NCT02897375` - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors	Phase 1
Completed	`NCT01672684` - Phase I: At-Home Support for Rural Women Using Group Video Calling	Phase 1
Terminated	`NCT01149356` - RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer	Phase 1